Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 3,121 | 1,560 | 1,135 | 749 | 415 |
| Cost of Goods | 465 | 190 | -461 | 305 | 374 |
| Gross Profit | 2,656 | 1,370 | 1,596 | 444 | 41 |
| Operating Expenses | 3,092 | 2,636 | 3,005 | 1,504 | 2,018 |
| Operating Income | -436 | -1,266 | -1,409 | -1,060 | -1,977 |
| Interest Expense | 1 | 1 | N/A | N/A | 0 |
| Other Income | 41 | 39 | 240 | 898 | 150 |
| Pre-tax Income | -396 | -1,228 | -1,169 | -162 | -1,827 |
| Income Tax | 0 | 0 | 1 | 0 | 0 |
| Net Income Continuous | -396 | -1,228 | -1,170 | -162 | -1,827 |
| Minority Interests | -124 | -42 | -37 | -6 | 91 |
| Net Income | $-520 | $-1,270 | $-1,207 | $-168 | $-1,736 |
| EPS Basic Total Ops | -0.13 | -0.33 | -0.33 | -0.07 | -0.46 |
| EPS Basic Continuous Ops | -0.13 | -0.33 | -0.33 | -0.07 | -0.46 |
| EPS Diluted Total Ops | -0.13 | -0.33 | -0.33 | -0.07 | -0.46 |
| EPS Diluted Continuous Ops | -0.13 | -0.33 | -0.33 | -0.07 | -0.46 |
| EBITDA(a) | $-386 | $-1,220 | $984 | $-1,056 | $-1,822 |